Article
Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status.
International journal of urology : official journal of the Japanese Urological Association - 1 Sept 2026
Nukaya Takuhisa, Naiki Taku, Watanabe Hiromitsu, Nakane Keita, Inamoto Teruo, Yasui Takahiro, Koie Takuya, Takahara Kiyoshi
Abstract excerpt
OBJECTIVES: Metastatic castration-resistant prostate cancer has a poor prognosis. Although olaparib has demonstrated efficacy in patients with BRCA1/2 mutations, real-world data in Japanese patients remain limited. We aimed to evaluate the efficacy and safety of olaparib in patients with BRCA-mutated metastatic castration-resistant prostate cancer and explore the association of BRCA2 loss and microsatellite...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.